Loading...
Dermata Therapeutics, Inc.
DRMAW•NASDAQ
HealthcareBiotechnology
$0.02
$-0.01(-32.75%)
Dermata Therapeutics, Inc. (DRMAW) Stock Overview
Explore Dermata Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for DRMAWStats details for DRMAW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for DRMAWAnalyst Recommendations details for DRMAW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2014 and is headquartered in San Diego, California.
CEO
Mr. Gerald T. Proehl
Employees
8
Headquarters
3525 Del Mar Heights Road, San Diego, CA
Founded
2021